Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

about

The Rapalogue, CCI-779, improves salivary gland function following radiation.A20/TNFAIP3 Discriminates Tumor Necrosis Factor (TNF)-Induced NF-κB from JNK Pathway Activation in Hepatocytes.

P2860

Q35463371-26E4B644-FE2F-43E6-A047-E06AF7BD55BC Q41526866-87040C86-7B62-461C-9E2E-C7C7804D61E1

P2860

Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

Item

http://www.wikidata.org/entity/Q41888593

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Everolimus immunosuppression r ...... n liver transplant recipients.

@en

type

Item

label

Everolimus immunosuppression r ...... n liver transplant recipients.

@en

prefLabel

Everolimus immunosuppression r ...... n liver transplant recipients.

@en

P1476

Everolimus immunosuppression r ...... in liver transplant recipients

@en

P2093

Ainhoa Fernández-Yunquera

http://www.w3.org/2001/XMLSchema#string

Cristina Ripoll

http://www.w3.org/2001/XMLSchema#string

Ismael Yepes

http://www.w3.org/2001/XMLSchema#string

Magdalena Salcedo

http://www.w3.org/2001/XMLSchema#string

Marta Puerto

http://www.w3.org/2001/XMLSchema#string

Vega Catalina

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis

Liver fibrosis

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.

Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.

Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.

Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study.

Surgical biology for the clinician: vascular effects of immunosuppression

Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis

Non-Smad TGF-beta signals.

The impact of sirolimus on hepatitis C recurrence after liver transplantation.

P304

133-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5500/WJT.V4.I2.133

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rafael Bañares

Diego Rincón

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25032102

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

4094948

http://www.w3.org/2001/XMLSchema#string

Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

about

P2860

P2860

Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932